After LivaNova announced that it has obtained Japanese national reimbursement for its Perceval sutureless aortic valve, Piper Jaffray analyst Matt O’Brien said he believes the announcement should be a “solid win” for the company that boosts growth in 2019 and 2020. O’Brien keeps an Overweight rating on LivaNova shares ahead of the company’s earnings call next week.
https://thefly.com/landingPageNews.php?id=2867945
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.